From rxpgnews.com
MN-001 : A Novel Drug for Asthma in Phase II Clinical Trial
By MediciNova, Inc,
Mar 29, 2005 - 12:07:38 PM
MediciNova, Inc., a specialty pharmaceutical company that is publicly traded on the Hercules Market of the Osaka Securities Exchange (Code number: 4875), today announced the enrollment of patients in a Phase II clinical study with MN-001, a novel, orally administered drug that was licensed from Kyorin Pharmaceutical Co. Ltd. of Tokyo, Japan. MN-001 is a leukotriene receptor antagonist and an inhibitor of phosphodiesterases III and IV, 5-lipoxygenase, as well as thromboxane A2.
Under the licensing agreement with Kyorin, MediciNova obtained exclusive worldwide rights, except for Japan, China, Taiwan and South Korea, to develop and commercialize MN-001.
According to the National Institutes of Health, asthma afflicts 3-5% of adults and 7-10% of children in the United States.
"We are enthusiastic about the potential for MN-001 to treat a broad range of patients with asthma," commented Takashi Kiyoizumi, President and CEO of MediciNova. "The pharmacology of MN-001 is unique and far-ranging, and we are hopeful that a greater proportion of asthmatics will respond to treatment."
All rights reserved by RxPG Medical Solutions Private Limited ( www.rxpgnews.com )